Ubiquitous Aberration in Cholesterol Metabolism Across Pancreatic Ductal Adenocarcinoma
Overview
Authors
Affiliations
Pancreatic cancer (PC) is characterized by metabolic deregulations that often manifest as deviations in metabolite levels and aberrations in their corresponding metabolic genes across the clinical specimens and preclinical PC models. Cholesterol is one of the critical metabolites supporting PC, synthesized or acquired by PC cells. Nevertheless, the significance of the de novo cholesterol synthesis pathway has been controversial in PC, indicating the need to reassess this pathway in PC. We utilized preclinical models and clinical specimens of PC patients and cell lines and utilized mass spectrometry-based sterol analysis. Further, we also performed in silico analysis to corroborate the significance of de novo cholesterol synthesis pathway in PC. Our results demonstrated alteration in free sterol levels, including free cholesterol, across in vitro, in vivo, and clinical specimens of PC. Especially, our sterol analyses established consistent alterations in free cholesterol across the different PC models. Overall, this study demonstrates the significance and consistency in deviation of cholesterol synthesis pathway in PC while showing the aberrations in sterol metabolite intermediates and the related genes using preclinical models, in silico platforms, and the clinical specimens.
Hashimoto A, Hashimoto S Cancers (Basel). 2024; 16(23).
PMID: 39682280 PMC: 11640101. DOI: 10.3390/cancers16234094.
DHCR24 in Tumor Diagnosis and Treatment: A Comprehensive Review.
Fu X, Wang Z Technol Cancer Res Treat. 2024; 23:15330338241259780.
PMID: 38847653 PMC: 11162140. DOI: 10.1177/15330338241259780.
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
Duan X, Zhang T, Feng L, de Silva N, Greenspun B, Wang X Cell Stem Cell. 2023; 31(1):71-88.e8.
PMID: 38151022 PMC: 11022279. DOI: 10.1016/j.stem.2023.11.011.
Li Y, Amrutkar M, Finstadsveen A, Dalen K, Verbeke C, Gladhaug I Cancer Cell Int. 2023; 23(1):276.
PMID: 37978383 PMC: 10657020. DOI: 10.1186/s12935-023-03138-8.
Cholesterol Metabolism in Pancreatic Cancer.
Rebelo A, Kleeff J, Sunami Y Cancers (Basel). 2023; 15(21).
PMID: 37958351 PMC: 10650553. DOI: 10.3390/cancers15215177.